ENDRA Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2015
Net Income	-10.06	-13.18	-11.35	-12.12	-17.53	Upgrade
Depreciation & Amortization	0.28	0.23	0.22	0.17	0.12	Upgrade
Share-Based Compensation	1	1.2	1.44	2.1	1.4	Upgrade
Other Operating Activities	-0.76	-1.02	-1.56	-1.29	3.2	Upgrade
Operating Cash Flow	-9.55	-12.77	-11.12	-10.75	-8.59	Upgrade
Capital Expenditures	-0.02	-0.2	-0.05	-0.08	-0.04	Upgrade
Investing Cash Flow	-0.02	-0.2	-0.05	-0.08	-0.04	Upgrade
Share Issuance / Repurchase	6.5	8.4	10.62	6.78	0.13	Upgrade
Debt Issued / Paid	0	0	0	0.34	2.49	Upgrade
Other Financing Activities	1.01	-	2.79	4.76	5.72	Upgrade
Financing Cash Flow	7.52	8.4	13.4	11.88	8.34	Upgrade
Net Cash Flow	-2.06	-4.57	2.23	1.05	-0.3	Upgrade
Free Cash Flow	-9.57	-12.97	-11.17	-10.82	-8.63	Upgrade
Free Cash Flow Per Share	-1.50	-4.49	-5.46	-11.28	-23.02	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).